Although some differences in growth rate were observed at early stages of development, all the cv.
The further development of the PSI-MS CV is an ongoing process.
The parthenocarpic development of the fruit in the cv.
Furthermore, despite a large cumulative patient exposure to linagliptin, individual patient exposure was for a maximum of 2.2 years, so the time available for the development of CV events, or modulation of CV risk, was limited.
CRP may therefore facilitate the development of diverse CV diseases via its influence on the events mediated by NO, prostacyclin, and endothelin-1.
Risk factors in childhood create a life-long burden important in the development of cardiovascular (CV) disease in adulthood.
Renal dysfunction has been shown an independent risk factor for the development of cardiovascular (CV) diseases [ 1, 2] and is associated with worsened outcome in patients with hypertension [ 3], post myocardial infarction (MI) [ 4, 5], and a broad spectrum of patients with left ventricular dysfunction [ 6, 7].
The progressive development of cardiovascular (CV) disease (CVD) resulting from pathophysiological changes mediated by angiotensin II in the presence of risk factors is well established [ 2] and local activation of RAS in the vascular walls is thought to contribute to atherosclerosis [ 5].
The key inclusion criteria for the trial were that patients had established CV disease or increased risk for the development of CV disease.
Of relevance, compared with awake or 24-h BP means, nocturnal BP levels have been shown to be superior in predicting CV morbidity and mortality (24– 28, 28, 46, 47), the development of CV events (24, 25, 40– 42), and overall mortality (24– 26, 41, 44, 45).
